Literature DB >> 30604625

Inositol monophosphatase 1 as a novel interacting partner of RAGE in pulmonary hypertension.

Ruslan Rafikov1, Matthew L McBride1, Marina Zemskova1, Sergey Kurdyukov1, Nolan McClain1, Maki Niihori1, Paul R Langlais1, Olga Rafikova1.   

Abstract

Pulmonary arterial hypertension (PAH) is a lethal disease characterized by progressive pulmonary vascular remodeling. The receptor for advanced glycation end products (RAGE) plays an important role in PAH by promoting proliferation of pulmonary vascular cells. RAGE is also known to mediate activation of Akt signaling, although the particular molecular mechanism remains unknown. This study aimed to identify the interacting partner of RAGE that could facilitate RAGE-mediated Akt activation and vascular remodeling in PAH. The progressive angioproliferative PAH was induced in 24 female Sprague-Dawley rats ( n = 8/group) that were randomly assigned to develop PAH for 1, 2, or 5 wk [right ventricle systolic pressure (RVSP) 56.5 ± 3.2, 63.6 ± 1.6, and 111.1 ± 4.5 mmHg, respectively, vs. 22.9 ± 1.1 mmHg in controls]. PAH triggered early and late episodes of apoptosis in rat lungs accompanied by RAGE activation. Mass spectrometry analysis has identified IMPA1 as a novel PAH-specific interacting partner of RAGE. The proximity ligation assay (PLA) confirmed the formation of RAGE/IMPA1 complex in the pulmonary artery wall. Activation of IMPA1 in response to increased glucose 6-phosphate (G6P) is known to play a critical role in inositol synthesis and recycling. Indeed, we confirmed a threefold increase in G6P ( P = 0.0005) levels in lungs of PAH rats starting from week 1 that correlated with accumulation of phosphatidylinositol (3,4,5)-trisphosphate (PIP3), membrane translocation of PI3K, and a threefold increase in membrane Akt levels ( P = 0.02) and Akt phosphorylation. We conclude that the formation of the newly discovered RAGE-IMPA1 complex could be responsible for the stimulation of inositol pathways and activation of Akt signaling in PAH.

Entities:  

Keywords:  glycolysis; inositol pathway; proliferation; pulmonary hypertension; receptor for advanced glycation end products

Mesh:

Substances:

Year:  2019        PMID: 30604625      PMCID: PMC6425619          DOI: 10.1152/ajplung.00393.2018

Source DB:  PubMed          Journal:  Am J Physiol Lung Cell Mol Physiol        ISSN: 1040-0605            Impact factor:   5.464


  6 in total

1.  Necrosis-Released HMGB1 (High Mobility Group Box 1) in the Progressive Pulmonary Arterial Hypertension Associated With Male Sex.

Authors:  Marina Zemskova; Nolan McClain; Maki Niihori; Mathews V Varghese; Joel James; Ruslan Rafikov; Olga Rafikova
Journal:  Hypertension       Date:  2020-10-05       Impact factor: 10.190

2.  Glucose-6-phosphate dehydrogenase deficiency contributes to metabolic abnormality and pulmonary hypertension.

Authors:  Mathews Valuparampil Varghese; Joel James; Olga Rafikova; Ruslan Rafikov
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2021-01-27       Impact factor: 5.464

3.  Focus on Early Events: Pathogenesis of Pulmonary Arterial Hypertension Development.

Authors:  Olga Rafikova; Imad Al Ghouleh; Ruslan Rafikov
Journal:  Antioxid Redox Signal       Date:  2019-07-02       Impact factor: 8.401

4.  Sex-specific stress response and HMGB1 release in pulmonary endothelial cells.

Authors:  Marina Zemskova; Sergey Kurdyukov; Joel James; Nolan McClain; Ruslan Rafikov; Olga Rafikova
Journal:  PLoS One       Date:  2020-04-09       Impact factor: 3.240

5.  COVID-19 Salivary Protein Profile: Unravelling Molecular Aspects of SARS-CoV-2 Infection.

Authors:  Eduardo Esteves; Vera M Mendes; Bruno Manadas; Rafaela Lopes; Liliana Bernardino; Maria José Correia; Marlene Barros; Ana Cristina Esteves; Nuno Rosa
Journal:  J Clin Med       Date:  2022-09-22       Impact factor: 4.964

6.  Pulmonary Arterial Hypertension Induces a Distinct Signature of Circulating Metabolites.

Authors:  Ruslan Rafikov; Dawn K Coletta; Lawrence J Mandarino; Olga Rafikova
Journal:  J Clin Med       Date:  2020-01-14       Impact factor: 4.241

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.